Drug Discovery & Development
Breakthrough electrochemical technique may bring cost savings to drug companies
Researchers have developed a simple new method for the creation of hindered ether compounds, which are often important components of many drugs and commercial products. Hindered ethers have been traditionally difficult to manufacture, but scientists at Scripps Research have published a new electrochemistry technique in Nature on September 9, which allows these compounds to be produced faster and more efficiently. Read More
The drug development industry is hungry for 3D printing – from the 4th Peptide Drug Design & Delivery Summit
The Science Advisory Board attended the 4th Annual Peptide Drug Design and Delivery Summit in Philadelphia from August 27 to 29. One of the most discussed topics at the event of the use of 3D printing for pharmaceutical applications. Many scientists are pursuing this technology with gusto, utilizing the technology to improve peptide drug design. Read More
Vaccine in development against hypervirulent Klebsiella
Concerns arising over the development of hypervirulent strains of Klebsiella pneumoniae have led researchers to develop an entirely new vaccine to protect against the gram-negative bacteria. A team of researchers at Washington University School of Medicine in St. Louis and VaxNewMo (a startup based in St. Louis) designed the vaccine by genetically manipulating E. coli. The details of the prototype designed were published in the Proceedings of the National Academy of Sciences on August 27th. Read More
Success of immunotherapies increased in cancer patients through co-treatment with monoclonal antibodies
A new approach provides evidence that it is possible to break down the protective wall surrounding tumor cells, therefore making immunotherapies more effective in patients with a variety of cancers. This research, funded by Cancer Research UK, was published in the EBioMedicine on August 25th. Read More
Oncogene identified as a therapeutic target for liver cancer
The function of an enzyme that is highly expressed in many cancers has been revealed to regulate key pathways in cancer metabolic adaptation. Researchers at the Georgia Cancer Center and Medical College of Georgia at Augusta University published their findings in Hepatology. Read More
New drug target identified for common brain cancer
Research led by the Cleveland Clinic has identified a potential new therapy in the treatment of glioblastoma. An article published in Cancer Discovery on August 21, identifies FGF2 (fibroblast growth factor 2), as a novel drug target for glioblastoma, the most common primary malignant brain tumor. Read More
Biologically active molecules in coal are found to have antiviral properties against tick-borne encephalitis
Scientists from Russia demonstrated in a Scientific Reports article published on August 19, that biologically active molecular components of substances extracted from coal, humic substances, have antiviral properties. A novel approach to identify these molecules determined that these molecules inhibit the reproduction of tick-borne encephalitis virus (TBEV), which causes clinically relevant human viral infectious disease. Read More
Top scientists ousted – potential impacts on mistrust of scientists in the US
Novartis dismissed the top two scientists at its gene therapy division shortly after CEO, Vas Narasimhan, learned of internal data falsification. This controversy comes at a time of high public trust in science and threatens to break that trust with scandals and safety concerns. Read More
The Parkinson’s Foundation launches large-scale genetic study, aiming to improve patient care and speed clinical trials
More than 10 million people worldwide are currently living with Parkinson’s disease (PD), a neurodegenerative disorder that impacts the dopamine-producing neurons in the brain. Scientists do not know exactly what causes PD, but they believe it is a combination of genetic and environmental factors. Nearly 10% to 15% of all PD cases are caused by genetic mutations. A new study aims to understand how the disease develops and how it can be treated or cured. This study, PD GENEration: Mapping the Future of Parkinson’s Disease is currently being conducted by the Parkinson’s Foundation. Read More
Large-scale analysis of microbiome reveals new classes of small proteins with implications in drug discovery
Trillion of bacteria reside within our bodies, and scientists are just scratching the surface of understanding the microbiome. Researchers at Stanford School of Medicine have shed light on previously unidentified proteins that may have an important role in human health and advance drug development. Read More
Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter